Article Details

Pfizer hopes Gilead's CD47 issues aren't catching | Evaluate

Retrieved on: 2022-01-26 19:17:14

Tags for this article:

Click the tags to see associated articles and topics

Pfizer hopes Gilead's CD47 issues aren't catching | Evaluate. View article details on hiswai:

Excerpt

Notably, Pfizer's TTI-621 and TI-622 are not being trialled alongside azacitidine, but other CD47 contenders are, including ALX Oncology's ...

Article found on: www.evaluate.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up